Interpreting biomarker data from the COPHES/DEMOCOPHES twin projects: Using external exposure data to understand biomarker differences among countries KU Leuven University of Antwerp
Testing of the OMERACT 8 Draft Validation Criteria for a Soluble Biomarker Reflecting Structural Damage in Rheumatoid Arthritis: A Systematic Literature Search on 5 Candidate Biomarkers Hasselt University
Bayesian biomarker-driven outcome-adaptive randomization with an imperfect biomarker assay Hasselt University
Diagnostic Impact of Cerebrospinal Fluid Biomarker (Pre-)Analytical Variability in Alzheimer's Disease Vrije Universiteit Brussel University of Antwerp
Intra- and inter-laboratory variability of cerebrospinal fluid (CSF) biomarker analyses remains an important issue. We investigated the clinical-diagnostic impact of CSF biomarker concentration shifts in mild cognitive impairment (MCI) and autopsy-confirmed Alzheimer's disease (AD) dementia patients. MCI patients (n = 85), autopsy-confirmed AD dementia patients (n = 72), and cognitively healthy controls (n = 100) were included in this ...
Total polyphenol intake is inversely associated with a pro/anti-inflammatory biomarker ratio in European adolescents of the HELENA study Ghent University
Combining traditional dietary assessment methods with novel metabolomics techniques : present efforts by the Food Biomarker Alliance Ghent University
Importance and impact of preanalytical variables on Alzheimer disease biomarker concentrations in cerebrospinal fluid Vrije Universiteit Brussel University of Antwerp
BACKGROUND: Analyses of cerebrospinal fluid (CSF) biomarkers (β-amyloid protein, total tau protein, and hyperphosphorylated tau protein) are part of the diagnostic criteria of Alzheimer disease. Different preanalytical sample procedures contribute to variability of CSF biomarker concentrations, hampering between-laboratory comparisons. The aim of this study was to explore the influence of fractionated sampling, centrifugation, freezing ...
The clinical use of cerebrospinal fluid biomarker testing for Alzheimer's disease diagnosis Vrije Universiteit Brussel University of Antwerp
BACKGROUND: Cerebrospinal fluid (CSF) biomarkers β-amyloid 1-42 (Aβ1-42), also expressed as Aβ1-42:Aβ1-40 ratio, T-tau, and P-tau181P, have proven diagnostic accuracy for mild cognitive impairment and Alzheimer's disease (AD). How to use, interpret, and disclose biomarker results drives the need for standardization.
METHODS: Previous Alzheimer's Biomarkers Standardization Initiative meetings discussed preanalytical issues affecting ...
Validation of Plasma Proteomic Biomarkers Relating to Brain Amyloid Burden in the EMIF-Alzheimer's Disease Multimodal Biomarker Discovery Cohort Vrije Universiteit Brussel KU Leuven
We have previously investigated, discovered, and replicated plasma protein biomarkers for use to triage potential trials participants for PET or cerebrospinal fluid measures of Alzheimer's disease (AD) pathology. This study sought to undertake validation of these candidate plasma biomarkers in a large, multi-center sample collection. Targeted plasma analyses of 34 proteins with prior evidence for prediction of in vivo pathology were conducted ...